Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of
lucinactant for inhalation, administered as an aerosolized dose in up to four escalating
doses to preterm neonates 26 to 28 weeks gestational age who are receiving nasal continuous
positive airway pressure (nCPAP) for respiratory distress syndrome (RDS) compared to
neonates receiving nCPAP alone.